Reaction
Chronic Myeloid Leukaemia Transformation reporting signals
As of the last recalculation, Chronic Myeloid Leukaemia Transformation appears in 440 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is NILOTINIB (PRR 295.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nilotinib | 130 | 295.6 | 296.9 |
| Imatinib | 55 | 168.4 | 169.0 |
| Imatinib Mesylate | 44 | 82.8 | 82.9 |
| Dasatinib | 52 | 74.9 | 75.0 |
| Bosutinib | 11 | 59.4 | 59.5 |
| Hydroxyurea | 20 | 46.8 | 46.9 |